SCHEDULE: Intracoastal Capital Discloses 9.4% Stake in Silexion

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 9.4% beneficial ownership stake in Silexion Therapeutics Corp.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") beneficially own 325,000 Ordinary Shares of Silexion Therapeutics Corp.
• This ownership represents approximately 9.4% of the company's Ordinary Shares.
• The beneficial ownership is comprised of 162,500 Ordinary Shares issuable upon exercise of Intracoastal Warrant 1 and 162,500 Ordinary Shares issuable upon exercise of Intracoastal Warrant 2.
• An additional 32,100 Ordinary Shares from Intracoastal Warrant 3 are excluded from this calculation due to a blocker provision that limits beneficial ownership to 4.99%.
• The percentage of class is calculated based on 3,126,642 Ordinary Shares outstanding as of November 9, 2025, plus the exercisable warrants.
• The Reporting Persons share both voting and dispositive power over the 325,000 shares.
• The securities were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the disclosure of a significant 9.4% beneficial ownership stake by Intracoastal Capital and its principals suggests a notable level of investor confidence in Silexion Therapeutics Corp, albeit as a passive investment.

Positives

• A significant beneficial ownership stake of 9.4% by institutional investors and individuals may signal confidence in Silexion Therapeutics Corp.
• The Reporting Persons explicitly state that the securities were not acquired for the purpose of changing or influencing control, which can alleviate concerns about activist investor intentions.

Negatives

• The filing itself does not contain negative financial or operational information about Silexion Therapeutics Corp.

Risks

• The filing does not explicitly detail operational, market, or financial risks for Silexion Therapeutics Corp.
• The blocker provision on Intracoastal Warrant 3, which limits beneficial ownership to 4.99%, is a structural detail that prevents the holder from exceeding a certain ownership threshold, potentially to avoid triggering additional regulatory reporting requirements or scrutiny.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that a Schedule 13G filing indicates a passive investment stake, typically by institutional investors or large individual holders, rather than an activist position. For Silexion Therapeutics, this disclosure highlights a significant ownership position by Intracoastal Capital and its principals, which can be viewed by the market as a vote of confidence, similar to other biotech or pharmaceutical companies attracting substantial institutional investment.

Stakeholder Impact

• Shareholders: The disclosure of a significant beneficial owner can influence market perception and potentially share price, signaling institutional interest.
• Company Management: Awareness of a large passive shareholder group may influence strategic decisions, though the filing explicitly states no intent to influence control.

Key Dates

Recommendation

While the disclosure of a significant 9.4% beneficial ownership stake by Intracoastal Capital and its principals might be interpreted as a positive signal of investor confidence, a Schedule 13G filing primarily serves as a regulatory disclosure of passive ownership. It does not provide sufficient fundamental or operational data to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further financial or strategic updates from Silexion Therapeutics Corp to make a more informed investment decision, using this ownership disclosure as one data point among many.

Keywords

Silexion Therapeutics, Intracoastal Capital, Mitchell Kopin, Daniel Asher, Schedule 13G, beneficial ownership, ordinary shares, warrants, SEC filing, institutional ownership